Related Experiment Video
Updated: Feb 6, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
Cell-free mitochondrial DNA in progressive multiple sclerosis
Hannah Lowes1, Angela Pyle1, Martin Duddy2
1Institute of Genetic Medicine, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK; The Wellcome Centre for Mitochondrial Research, Newcastle University, Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
Abstract:
Recent studies have linked cell-free mitochondrial DNA (ccf-mtDNA) to neurodegeneration in both Alzheimer's and Parkinson's disease, raising the possibility that the same phenomenon could be seen in other diseases which manifest a neurodegenerative component. Here, we assessed the role of circulating cell-free mitochondrial DNA (ccf-mtDNA) in end-stage progressive multiple sclerosis (PMS), where neurodegeneration is evident, contrasting both ventricular cerebral spinal fluid ccf-mtDNA abundance and integrity between PMS cases and controls, and correlating ccf-mtDNA levels to known protein markers of neurodegeneration and PMS. Our data indicate that reduced ccf-mtDNA is a component of PMS, concluding that it may indeed be a hallmark of broader neurodegeneration.
Insights
Reduced cell-free mitochondrial DNA (ccf-mtDNA) is linked to progressive multiple sclerosis (PMS), a neurodegenerative disease. This finding suggests ccf-mtDNA may be a biomarker for widespread neurodegeneration.
Area of Science:
- Neuroscience
- Molecular Biology
- Immunology
Background:
- Cell-free mitochondrial DNA (ccf-mtDNA) is implicated in neurodegeneration in Alzheimer's and Parkinson's diseases.
- Progressive multiple sclerosis (PMS) exhibits significant neurodegenerative components.
Purpose of the Study:
- To investigate the role of circulating ccf-mtDNA in end-stage progressive multiple sclerosis (PMS).
- To compare ccf-mtDNA abundance and integrity in cerebrospinal fluid between PMS patients and controls.
- To correlate ccf-mtDNA levels with established neurodegeneration and PMS protein markers.
Main Methods:
- Analysis of ventricular cerebrospinal fluid (CSF) ccf-mtDNA abundance and integrity.
- Comparison between PMS cases and healthy controls.
- Correlation of ccf-mtDNA levels with protein markers of neurodegeneration and PMS.
Main Results:
- Reduced levels of ccf-mtDNA were observed in patients with progressive multiple sclerosis.
- ccf-mtDNA integrity may also be altered in PMS.
- ccf-mtDNA levels showed correlations with specific protein markers.
Conclusions:
- Reduced ccf-mtDNA is a characteristic feature of progressive multiple sclerosis.
- ccf-mtDNA may serve as a potential biomarker for neurodegeneration in a broader range of diseases.
Related Concept Videos
Animal Mitochondrial Genetics
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
Export of Mitochondrial and Chloroplast Genes
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Multiple Allele Traits
From DNA to Protein

